St. Jude Medical on Thursday announced results of a 10-year follow-up study that showed patients with a basic, shock-only defibrillator lived longer than heart patients without such a device.
The results of the Sudden Cardiac Death in Heart Failure Trial were released during the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston. According to St. Jude, the study demonstrated that implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure.
The study was led by Dr. Gust H. Bardy at the Seattle Institute for Cardiac Research and was sponsored by the National Heart, Lung, and Blood Institute and the National Institutes of Health, with a grant provided by St. Jude Medical. It bolsters the results of an original trial.
"While the original findings of the SCD-HeFT trial advanced the standard of care for patients with heart failure, the follow-up data are critical to define long-term ICD mortality benefits,” said Dr. Jeanne Poole, Professor of Medicine at the University of Washington, who presented the data at Heart Rhythm 2012. “The SCD-HeFT findings demonstrate that patients experience the lifesaving benefit of ICD therapy over a decade of clinical heart failure.”
Dr. Mark Carlson, chief medical officer and a senior vice president at St. Jude, said: “St. Jude Medical is proud to have supported the SCD-HeFT follow-up study, a trial that provides physicians with important information on the long-term efficacy of ICD therapy. We’ll continue to support trials providing physicians with clinically relevant information that can help them to improve patient outcomes.”